🔴 Opus Genetics is trading 5.69% down today after second-quarter revenue missed estimates

Opus Genetics is trading at $3.56, down 5.69%, after second-quarter revenue of $755,000 missed the $2.47 million estimate despite an EPS beat.

• Reported an $8.1 million net loss, while collaboration revenue declined year over year.
• Management highlighted $88.8 million in cash and runway into 2029, plus September BEST1 data.
• The revenue shortfall appears to outweigh pipeline updates and funding guidance during active trading.